Tissue Modeling and Drug Discovery Core

组织建模和药物发现核心

• 批准号: 10762213
• 负责人: Hernan Alcides Flores-Rozas
• 金额: $ 22.2万
• 依托单位: FLORIDA AGRICULTURAL AND MECHANICAL UNIV
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-19 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10762213
• 关键词: Address; African American; Archives; Basic Science; Biocompatible Materials; Bioinformatics; Black race; California; Caring; Cell Line; Chemistry; Collaborations; Collection; Complex; Conscious; Data; Databases; Development; Development Plans; Disparity; Education; Ensure; Evaluation; FDA approved; First Independent Research Support and Transition Awards; Florida; Funding; Future; Genomics; Goals; Hispanic; Human; Implant; Individual; Institution; Latinx; Latinx population; Lead; Leadership; Link; Malignant Neoplasms; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Medical Research; Mentorship; Methodology; Mission; Modeling; Molecular; Normal tissue morphology; Organoids; Outcome; Pathologic; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pilot Projects; Plasma; Population; Prostate; RNA; Race; Research; Research Personnel; Research Project Grants; Residual state; Resource Sharing; Resources; Role; Sampling; Scientist; Serum; Specimen; Technology; Testing; Tissue Banks; Tissue Model; Tissue Sample; Tissues; Translational Research; Tumor Tissue; Universities; anticancer research; biobank; cancer health disparity; cancer type; career development; clinical database; clinical translation; crosslink; drug development; drug discovery; ethnic diversity; experience; genomic data; health equity; member; neoplasm registry; novel; pancreatic cancer patients; patient derived xenograft model; patient population; racial diversity; recruit; repository; research and development; response; skills; success; technology development; tumor; virtual

ABSTRACT – TISSUE MODELING & DRUG DEVELOPMENT CORE (SHARED RESOURCE) The goal of the Florida-California Cancer Research, Education, & Engagement (CaRE2) Health Equity Center’s Tissue Modeling and Drug Development Core (TMDDC) is to provide a growing archive of fixed and living tissues that will support the mission of the CaRE2 Center. In the first funding period (Cycle 1), we were highly successful in gaining access for FAMU and CaRE2 researchers to annotated tissues from Black/African American (B/AA) and Hispanic/Latinx (H/L). In total, the TMDDC now has regulatory compliant access across the partnership to cancer cases including pancreatic cancer blocks (295 B/AA, 306 H/L), pancreatic cancer plasma/serum (136 B/AA, 53 H/L), prostate cancer blocks (548 B/AA, 195 H/L), and prostate plasma/serum (595 B/AA, 92 H/L). Also, the TMDDC facilitated creation or identification of 4 new patient-derived xenografts (PDX) from B/AA patients with pancreatic cancer for studies at FAMU and USC. The TMDDC will continue to develop a robust, well-annotated biorepository of fixed and living tissue samples from a racially and ethnically diverse Florida and California patient population and make them available to the CaRE2 investigators. The TMDDC will consist of existing institutional, nationally shared, and future-conscious biorepository resources. The short-term goals of the TMDDC are to provide the necessary tissue samples for the three projects included in this application, while preparing for the future needs of the existing and upcoming CaRE2 Center projects. The TMC will address the challenge of recruiting B/AA and H/L individuals in medical research and the limited supply of quality biospecimens and genomic data for these populations. Our specific aims are to: Aim 1. Advance our existing virtual and physical repositories that will increasingly provide biospecimens from diverse tumor repositories through a single access point provided by the CaRE2 Center. Many cancer types and many tissue models are relevant to outcomes in disparities research. The broad types of tissues and data required to study these complex issues make acquisition of a fully satisfactory repository beyond the scope of any single institution. Therefore, we will develop capabilities to collect or acquire novel diverse and well annotated specimens through our institutional resources and other resources. Aim 2. Acquire living tumor tissue for drug development. PDXs have proven to better predict human drug responses than historically used cell-line derived studies. Development of these PDXs has the potential to facilitate rapid drug development, including testing response as a function of race/ancestry. The TMDDC will advance the existing Cycle 1 developed tissue repository at FAMU. The TMDDC will advance on the existing living tissue repository at FAMU. By achieving these aims, we will: (1) enhance cancer disparities tissue-modeling research; (2) expand cancer disparities resources for CaRE2 researchers, and (3) ensure a sustained focus on transferring know-how, technology, and collaborations with FAMU. Evaluation will be based on adequate provision of project-required specimens/resources and by success in transferring drug development technology and knowhow to FAMU.

摘要 – 组织建模和药物开发核心（共享资源） 佛罗里达州-加利福尼亚州癌症研究、教育和参与 (CaRE2) 健康公平中心的目标 组织建模和药物开发核心（TMDDC）旨在提供不断增长的固定和活组织档案 这将支持 CaRE2 中心的使命。在第一个融资期（Cycle 1），我们非常成功 帮助 FAMU 和 CaRE2 研究人员获取黑人/非裔美国人 (B/AA) 的注释组织 和西班牙裔/拉丁裔 (H/L)。总的来说，TMDDC 现在在整个合作伙伴关系中拥有符合监管要求的访问权限 癌症病例，包括胰腺癌块（295 B/AA，306 H/L）、胰腺癌血浆/血清（136 B/AA，53 H/L）、前列腺癌块（548 B/AA，195 H/L）和前列腺血浆/血清（595 B/AA，92 H/L）。 此外，TMDDC 还促进了 4 个来自 B/AA 的新患者来源异种移植物 (PDX) 的创建或鉴定 患有胰腺癌的患者在 FAMU 和 USC 进行研究。 TMDDC 将继续开发一个强大的、 来自佛罗里达州不同种族和民族的固定和活组织样本的注释明确的生物样本库 加州患者群体，并将其提供给 CaRE2 研究人员。 TMDDC 将包括 现有的、全国共享的、面向未来的机构生物保藏资源。短期目标 TMDDC 将为本申请中包含的三个项目提供必要的组织样本，同时 为现有和即将到来的 CaRE2 中心项目的未来需求做好准备。 TMC 将解决 在医学研究中招募 B/AA 和 H/L 人员的挑战以及质量供应有限 这些人群的生物样本和基因组数据。我们的具体目标是： 目标 1. 推进我们现有的 虚拟和物理存储库将越来越多地提供来自不同肿瘤存储库的生物样本 通过 CaRE2 中心提供的单一接入点。许多癌症类型和许多组织模型 与差异研究的结果相关。研究这些复杂的组织和数据所需的广泛类型 这些问题使得获得一个完全令人满意的存储库超出了任何单一机构的范围。所以， 我们将通过我们的技术开发收集或获取新颖多样且注释清楚的标本的能力 机构资源和其他资源。目标 2. 获取活体肿瘤组织用于药物开发。 PDX 事实证明，与历史上使用的细胞系衍生研究相比，可以更好地预测人类药物反应。发展 这些 PDX 具有促进快速药物开发的潜力，包括测试反应作为 种族/血统。 TMDDC 将推进 FAMU 现有的第一周期开发的组织储存库。 TMDDC 将推进 FAMU 现有的活组织储存库。通过实现这些目标，我们将：（1）增强 癌症差异组织模型研究； (2) 为 CaRE2 研究人员扩大癌症差异资源， (3) 确保持续关注转让专业知识、技术以及与 FAMU 的合作。 评估将基于是否充分提供了项目所需的标本/资源以及是否成功 向 FAMU 转让药物开发技术和专业知识。